Kushen extract (oxymatrine / matrine)
Oxymatrine / Matrine (Sophora Flavescens) · also known as Oxymatrine, Matrine, Kushen extract, Oxymatrine
Oxymatrine is an alkaloid from kushen. Animal and cell studies show it affects TGF-β1 and TLR4 signaling. In a randomized placebo-controlled trial at 900 mg/day, liver fibrosis scores improved in some re-assessed patients. That dose is higher than the 200–600 mg/day listed here.
Clinical uses and human evidence
Fatty liver and liver enzymes
Studies (2)
- Song 2016 · Chin J Integr Med · Meta-analysis · n=5227 — Oral oxymatrine preparation for chronic hepatitis B: A systematic review of randomized controlled trials
- Lu 2003 · World J Gastroenterol · RCT · n=216 — Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial
Mechanisms of action
Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription
In an animal cerebral ischemia model, oxymatrine downregulated TLR4, MyD88 and NF-κB-related expression in brain tissue. In cell experiments, nuclear translocation of p65 decreased. In mice, colitis was reduced, but the overall NF-κB reporter signal did not change. These results do not yet show that it strongly shuts off inflammatory transcription at usual oral doses in humans.
References (2)
Collagen triple-helix cross-linking and fibril synthesis
In human oral trials, markers of collagen turnover fell, and only some participants had repeat biopsies. This does not mean that collagen cross-linking was promoted, and it does not prove that the Smad pathway is inhibited in humans. In studies using intravenous administration, serum TGF-β1 fell, but whether oral dosing suppresses Smad phosphorylation has not been directly confirmed.
References (2)
- Mao 2004 · Human randomized placebo-controlled trial: 900 mg/day orally; type III procollagen peptide improved, as did liver fibrosis scores in some patients who were re-assessed.
- Liang 2010 · Human randomized controlled study: serum TGF-β1 fell in the intravenous group; it was not directly shown that oral dosing suppresses Smad phosphorylation.
Mast cell membrane stabilization and degranulation blockade
In cell experiments, histamine and degranulation markers decreased in RBL-2H3 cells. Improvement in animal dermatitis alone also cannot prove that degranulation is blocked in vivo. It is not clear whether oral dosing reaches effective tissue exposure in humans, and eosinophils should not be treated as equivalent to mast cells.